secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akoya Biosciences, Inc. (—)
CIK:        0001711933
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001558370-24-010858
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akoya Biosciences Q2 revenue $23.2M, up 26% sequentially; COO retiring; FY guidance $96-104M
--------------------------------------------------------------------------------

- Revenue $23.2M, up 26.2% sequentially from Q1 2024; YoY down 1.5% from $23.5M.
- Gross margin improved to 57.8% from 45.7% in Q1 2024 and 51.5% in Q2 2023.
- Operating loss narrowed to $11.1M from $21.6M in Q1 2024 and $19.2M in Q2 2023.
- Updated FY2024 revenue guidance $96-104M; reaffirms operating cash flow breakeven by year-end.
- COO Frederic Pla retiring effective August 16, 2024; will assist transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711933/000155837024010858/0001558370-24-010858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711933/000155837024010858/akya-20240731x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-010858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer